Drugs /

gdc-6036

Back to Drugs List

Overview

NCI Definition [1]:
An orally available inhibitor of the oncogenic KRAS substitution mutation, G12C, with potential antineoplastic activity. Upon oral administration, KRAS G12C inhibitor GDC-6036 selectively targets the KRAS G12C mutant and inhibits KRAS G12C mutant-dependent signaling. KRAS, a member of the RAS family of oncogenes, serves an important role in cell signaling, division and differentiation. Mutations of KRAS may induce constitutive signal transduction leading to tumor cell growth, proliferation, invasion, and metastasis.

Clinical Trials

View Clinical Trials for gdc-6036

Gdc-6036 has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating gdc-6036, 1 is phase 1 (1 open).

KRAS G12C is the most frequent biomarker inclusion criterion for gdc-6036 clinical trials.

Colorectal carcinoma, malignant solid tumor, and non-small cell lung carcinoma are the most common diseases being investigated in gdc-6036 clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Gdc-6036
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating gdc-6036 and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
kras g12c inhibitor gdc-6036, gdc 6036, gdc6036
Drug Target(s) [2]:
KRAS
NCIT ID [1]:
C173995

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.